Pharmabiz5h
Eupraxia Pharma reports positive data from RESOLVE phase 1b/2a trial of EP-104GI for treatment of eosinophilic esophagitis
Victoria, British Columbia Thursday, November 14, 2024, 18:00 Hrs [IST] ...
North American Morning Briefing: Cautious Open -2-
Within two days of the election, Newsom positioned himself at the forefront of the opposition, calling for state lawmakers to convene an emergency special session "to safeguard California values" in ...
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
FiercePharma5d
AstraZeneca, Amgen's Tezspire scores in rhinosinusitis study
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
clinicaladvisor.com6d
Biologic Therapies for Psoriasis Linked to Increased GI Adverse Events
Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.
EuropaWire6d
Tezspire Shows Promise in Reducing Nasal Polyp Symptoms in Phase III Trial for Chronic Rhinosinusitis
17,18 TSLP is released in response to multiple triggers (including allergens, viruses and other airborne particles) ...
Pharmaceutical Technology6d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic Esophagitis
Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...
Pharmaceutical Technology7d
DBV Technologies’ stock slides as financial woes worsens
The company reported that it does not have sufficient cash reserves to operate for the next 12 months, can only fund operations into Q1 2025.
Daily7d
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis
Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...
Pharmabiz7d
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...